Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04645940 · ClinicalTrials.gov registry record · Phase 1

Fruquintinib Food Effect and Proton Pump Inhibitor Study

A Phase 1 study of Drug Interaction and Food-drug Interaction, sponsored by Hutchison Medipharma Limited.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
1
Study location

NCT04645940 is a Phase 1 study of Drug Interaction and Food-drug Interaction that has completed, run by Hutchison Medipharma Limited. The registered enrollment target is 14 participants, below the 94-participant average among 3 other Drug Interaction trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04645940, a Phase 1 study of Drug Interaction and Food-drug Interaction, has completed, sponsored by Hutchison Medipharma Limited.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

The purpose of this is to evaluate the effect of food and the effect of a proton pump inhibitor (rabeprazole) on the pharmacokinetics of fruquintinib.

Interventions

  • DRUG fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole
  • DRUG fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole

Study Locations (1)

California

  • WCCT - Cypress

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2020-09-24
Est. Completion 2020-11-18
Phase Phase 1

Sponsor

Hutchison Medipharma Limited

11 total trials

What the Registry Record Tells You About NCT04645940

The ClinicalTrials.gov registry entry for NCT04645940 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 3 other Drug Interaction trials with a reported enrollment target (85% lower). The listed sponsor is Hutchison Medipharma Limited, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Drug Interaction appearing as the primary indexed condition, and to 2 interventions - of which fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole is the first listed.

NCT04645940 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04645940 about?

NCT04645940 is a clinical study titled "Fruquintinib Food Effect and Proton Pump Inhibitor Study". The purpose of this is to evaluate the effect of food and the effect of a proton pump inhibitor (rabeprazole) on the pharmacokinetics of fruquintinib.

What is the current status of trial NCT04645940?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2020-09-24. Estimated completion is 2020-11-18.

What conditions does trial NCT04645940 study?

This clinical trial studies the following conditions: Drug Interaction, Food-drug Interaction.

What interventions are being tested in trial NCT04645940?

The interventions under investigation include: fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole (DRUG), fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole (DRUG).

Who is sponsoring clinical trial NCT04645940?

This trial is sponsored by Hutchison Medipharma Limited, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04645940 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Drug Interaction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.